Immunotherapy Clinical Trials in Beijing
9 recruitingBeijing, China
Showing 1–9 of 9 trials
Recruiting
Phase 3
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal CancerSurgeryChemotherapy Effect+4 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled1 locationNCT04821843
Recruiting
Phase 3
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
Esophagus CancerChemotherapy EffectTargeted Therapy+3 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences2,000 enrolled5 locationsNCT04821778
Recruiting
Not Applicable
Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
Colon CancerImmunotherapyMismatch Repair Deficiency
Peking Union Medical College Hospital18 enrolled2 locationsNCT06215677
Recruiting
Phase 2
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
Esophageal CancerSurgeryImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences60 enrolled3 locationsNCT06421376
Recruiting
Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy
Immunotherapy
jianming xu50 enrolled1 locationNCT06946745
Recruiting
Phase 2
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients
Non-small Cell Lung CancerConsolidation ImmunotherapyRadiotherapy or Sequential Chemoradiation
Peking University Cancer Hospital & Institute20 enrolled1 locationNCT05758116
Recruiting
Phase 2
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences55 enrolled1 locationNCT06429839
Recruiting
Phase 2
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Esophageal CancerChemotherapyImmunotherapy+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences53 enrolled1 locationNCT06410651
Recruiting
Phase 1
Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome
ImmunotherapyMyelodysplastic SyndromesDendritic Cell+1 more
Affiliated Hospital to Academy of Military Medical Sciences40 enrolled1 locationNCT04999943